PMID- 9552030
OWN - NLM
STAT- MEDLINE
DCOM- 19980512
LR  - 20220317
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 16
IP  - 4
DP  - 1998 Apr
TI  - Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s 
      downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic 
      adenocarcinomas.
PG  - 1302-9
AB  - PURPOSE: To test whether p34cdc2 overexpression, CD44s downregulation, and 
      HER-2/neu amplification correlate with disease recurrence after radical 
      prostatectomy, and to evaluate a possible biologic association between p34cdc2 
      and HER-2/neu expression. MATERIALS AND METHODS: Immunohistochemical (IHC) 
      detection of both p34cdc2 cyclin-dependent kinase (CDK) and CD44s expression and 
      fluorescence in situ hybridization (FISH)-based analysis of HER-2/neu gene status 
      were performed on formalin-fixed, paraffin-embedded sections of 106 prostatic 
      adenocarcinomas (PACs). Findings were correlated with Gleason grade, pathologic 
      stage, DNA ploidy, and postsurgical biochemical disease recurrence. RESULTS: CDK 
      overexpression correlated with tumor grade (P = .001), DNA ploidy (P = .001), 
      pathologic stage (P = .04), and disease recurrence (P = .01). CD44s 
      downregulation correlated with grade (P = .03), ploidy (P = .01), and recurrence 
      (P = .02). HER-2/neu amplification correlated with grade (P = .001), ploidy (P = 
      .001), and recurrence (P = .01). On multivariate analysis, CDK overexpression 
      independently predicted recurrence (P = .001) after prostatectomy. CDK expression 
      correlated with HER-2/neu status with 32 of 65 (49%) tumors that overexpressed 
      CDK and showed concomitant HER-2/neu amplification (P = .04). CONCLUSION: This 
      study showed that p34cdc2, CD44s, and HER-2/neu are variably expressed or 
      amplified in prostatic carcinoma and that such alteration may affect tumor 
      behavior. In addition, CDK overexpression and HER-2/neu amplification may be 
      biologically related.
FAU - Kallakury, B V
AU  - Kallakury BV
AD  - Department of Pathology and Laboratory Medicine, Albany Medical College, NY, USA.
FAU - Sheehan, C E
AU  - Sheehan CE
FAU - Ambros, R A
AU  - Ambros RA
FAU - Fisher, H A
AU  - Fisher HA
FAU - Kaufman, R P Jr
AU  - Kaufman RP Jr
FAU - Muraca, P J
AU  - Muraca PJ
FAU - Ross, J S
AU  - Ross JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Hyaluronan Receptors)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
SB  - IM
MH  - Adenocarcinoma/enzymology/genetics/*pathology/*surgery
MH  - Cyclin-Dependent Kinases/*metabolism
MH  - Down-Regulation
MH  - Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Hyaluronan Receptors/*metabolism
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Neoplasm Recurrence, Local/genetics
MH  - Ploidies
MH  - Prostatectomy
MH  - Prostatic Neoplasms/enzymology/genetics/*pathology/*surgery
EDAT- 1998/04/29 06:29
MHDA- 2001/03/28 10:01
CRDT- 1998/04/29 06:29
PHST- 1998/04/29 06:29 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1998/04/29 06:29 [entrez]
AID - 10.1200/JCO.1998.16.4.1302 [doi]
PST - ppublish
SO  - J Clin Oncol. 1998 Apr;16(4):1302-9. doi: 10.1200/JCO.1998.16.4.1302.